(24/7 MARKET NEWS) – Lucira Health, Inc. (Nasdaq: LHDX) announced, this morning, that the FDA granted emergency use authorization for its Lucira COVID-19 & Flu Home Test for over the counter use at home and other non-laboratory sites.
Lucira is at $0.503, up $0.363 (+259.29%), on 31.3 million premarket shares.
Its 52-week trading range is $0.108 to $5.67. This morning’s trading volume is massive and it’s cleared multiple key resistance points, but it did the same thing on the first trading day of 2023, so traders must be nimble.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
